|
Medtronic Plc (NYSE: MDT) |
|
|
|
|
Select the Financial Report:
|
|
Select the Period:
|
|
Description of Medtronic Plc's Business Segments
Medtronic plc is a renowned global leader in the development and manufacture of innovative medical technologies, providing a broad spectrum of products and therapies designed to enhance patient care across multiple therapeutic areas. Below is an extensive overview of the major segments, products, and services that Medtronic offers.
1. Cardiac Rhythm Management (CRM)
Medtronic has significantly advanced cardiac rhythm management, positioning itself as a premier supplier of devices that monitor, regulate, and treat various heart rhythm disorders.
Principal Products:
- Implantable Cardiac Devices: These encompass both permanent and temporary pacemakers specifically designed for bradycardia management. Prominent models include the EnPulse' pacemaker, which offers automated adjustments for optimal heart function alongside Atrial Capture Management (ACM).
- Implantable Cardioverter Defibrillators (ICDs): These critical devices are responsible for monitoring heart rhythms and delivering life-saving therapy to prevent Sudden Cardiac Arrest (SCA). Notable examples are the Maximo' ICD and the GEM III' AT defibrillator.
- Cardiac Resynchronization Therapy (CRT): Through devices like the InSync' family of systems, Medtronic aids heart failure patients by synchronizing heart chamber contractions to enhance overall heart function.
- External Defibrillators: The LIFEPAK' series of Automated External Defibrillators (AEDs) are designed for emergency medical responses, increasingly found in public spaces to improve survival rates during cardiac emergencies.
Patient Management Systems:
- Medtronic CareLink' Network: This remote patient management platform enables healthcare providers to monitor patients' device data from afar, fostering better long-term management of cardiac conditions and improving patient outcomes.
Spinal, Ear, Nose and Throat (ENT), and Surgical Navigation Technologies
This segment is dedicated to delivering innovative surgical solutions for spine disorders, ENT conditions, and advanced surgical navigation systems.
Principal Products:
- Spinal Surgery Systems: Medtronic provides a wide array of devices for spinal fusion, including thoracolumbar and cervical spinal implants, plates, and bone graft substitutes like INFUSE' Bone Graft, promoting the body's natural bone growth.
- Minimal Access Spinal Technologies (MAST): These technologies, exemplified by the CD HORIZON' system, facilitate minimally invasive procedures in spinal surgeries, reducing recovery time and improving surgical precision.
- ENT Surgical Products: This category includes advanced systems and devices for sinus surgery, powered surgical instruments, and navigation systems that enable precise targeting during various ENT procedures.
- Surgical Navigation Technologies: Tools like the StealthStation' Navigation System enhance surgical accuracy in spinal and cranial operations through real-time imaging and navigation capabilities.
Neurological and Diabetes
Medtronics offerings in neurological treatments and diabetes management encompass a robust range of products designed to improve the quality of life for patients affected by these conditions.
Neurological Products:
- Deep Brain Stimulation Systems: Products such as the Activa' Therapy are pivotal in treating movement disorders like Parkinson's disease, providing significant symptom relief for many patients.
- Drug Delivery Systems: Programmable infusion systems like the SynchroMed' deliver targeted pain relief, providing effective therapy options for chronic pain management.
Diabetes Management:
- Insulin Pumps: The Paradigm' series of insulin pumps enhances diabetes management by providing advanced delivery options, including integration with continuous glucose monitoring systems for real-time blood sugar management.
- Continuous Glucose Monitoring (CGM) Systems: Devices like the Guardian' system alert patients about dangerous fluctuations in blood sugar levels, improving management and overall health outcomes for individuals with diabetes.
Vascular
Medtronics vascular line addresses a variety of procedures related to coronary, peripheral, and endovascular care.
Principal Products:
- Coronary Products: This includes innovative drug-eluting stents like Endeavor' and Driver', which are designed to prevent the re-narrowing of coronary arteries following intervention.
- Endovascular Stent Grafts: For the repair of aortic aneurysms, Medtronic offers products such as AneuRx' and Talent' stent grafts, which are critical for endovascular surgeries.
- Peripheral Stents and Accessories: A comprehensive collection of devices and tools for treating peripheral artery disease, including balloon angioplasty catheters and guidewires.
Cardiac Surgery
Medtronic is a well-established leader in the cardiac surgery segment, offering an array of products that aid surgeons during complex operations.
Principal Products:
- Coronary Artery Bypass Grafting (CABG): Medtronic provides essential products for both arrested and beating heart surgeries, including circulatory support technologies and a variety of surgical instruments.
- Heart Valve Repair and Replacement: The company offers a wide range of mechanical and tissue valves, such as the Mosaic', Freestyle', and ADVANTAGE Supra' valves, facilitating effective valve repairs and replacements.
Surgical Technologies
The surgical technologies division is focused on delivering minimally invasive and image-guided surgical solutions.
Principal Products:
- ENT and Neurological Devices: Products such as the PEAK PlasmaBlade' and NIM' Nerve Monitoring Systems significantly enhance surgical outcomes and safety during ENT and neurological surgeries.
- Navigation Systems: Advanced imaging solutions, including the O-Arm' and PoleStar', greatly improve surgical accuracy in cranial and spinal operations, assisting surgeons in complex procedures.
Gastroenterology and Urology
Medtronic offers diagnostic and therapeutic solutions for gastrointestinal and urological disorders.
Principal Products:
- Gastroenterology Devices: This includes the Bravo' pH Monitoring System, which is utilized for assessing gastroesophageal reflux disease (GERD), and the Gatekeeper' Reflux Repair System, which provides therapeutic options for reflux management.
- Urology Devices: The InterStim' Therapy system addresses issues related to bladder control, while the TUNA' system offers a minimally invasive treatment option for benign prostatic hyperplasia (BPH), enhancing patient quality of life.
Conclusion
Medtronic plc remains at the forefront of medical device innovation with its diverse portfolio aimed at improving patient outcomes across numerous health conditions. The company's commitment to enhancing patient care through technological advancements and comprehensive management solutions reinforces its pivotal role in the medical device industry. As it continues to adapt to the evolving healthcare landscape, Medtronic is well-positioned to respond to emerging healthcare needs effectively.
Composition of Medtronic Plc Revenues by
Segments |
| |
| Reportable net sales |
|
 99.61 % |
of total Revenue |
| Cardiovascular |
|
36.63 % |
of total Revenue |
| Cardiovascular Cardiac Rhythm Heart Failure |
|
18.63 % |
of total Revenue |
| Cardiovascular Structural Heart Aortic |
|
10.54 % |
of total Revenue |
| Cardiovascular Coronary Peripheral Vascular |
|
7.45 % |
of total Revenue |
| Neuroscience |
|
29.64 % |
of total Revenue |
| Neuroscience Cranial Spinal Technologies |
|
15.07 % |
of total Revenue |
| Neuroscience Specialty Therapies |
|
8.83 % |
of total Revenue |
| Neuroscience Neuromodulation |
|
5.74 % |
of total Revenue |
| Medical Surgical |
|
24.99 % |
of total Revenue |
| Medical Surgical Surgical Endoscopy |
|
19.25 % |
of total Revenue |
| Medical Surgical Acute Care Monitoring |
|
5.74 % |
of total Revenue |
| Diabetes |
|
8.37 % |
of total Revenue |
| Other segment |
|
0.39 % |
of total Revenue |
| U S |
|
51.1 % |
of total Revenue |
| International |
|
48.9 % |
of total Revenue |
| Reportable net sales U S |
|
50.93 % |
of total Revenue |
| Reportable net sales International |
|
48.7 % |
of total Revenue |
| Cardiovascular U S |
|
16.94 % |
of total Revenue |
| Cardiovascular International |
|
19.68 % |
of total Revenue |
| Neuroscience U S |
|
20.37 % |
of total Revenue |
| Neuroscience International |
|
9.27 % |
of total Revenue |
| Medical Surgical U S |
|
10.77 % |
of total Revenue |
| Medical Surgical International |
|
14.23 % |
of total Revenue |
| Diabetes U S |
|
2.85 % |
of total Revenue |
| Diabetes International |
|
5.51 % |
of total Revenue |
| Other U S |
|
0.18 % |
of total Revenue |
| Other International |
|
0.21 % |
of total Revenue |
| Ireland |
|
0.34 % |
of total Revenue |
| Total other countries excluding Ireland |
|
99.66 % |
of total Revenue |
| United States |
|
51.1 % |
of total Revenue |
| Rest of world |
|
48.56 % |
of total Revenue |
Q3 three months ended (Jan 24 2025)
|
| Revenues by Business Segments |
Revenues
(in millions $) |
%
(of total Revenues) |
| Reportable net sales |
8,260.00 |
99.61 % |
| Cardiovascular |
3,037.00 |
36.63 % |
| Cardiovascular Cardiac Rhythm Heart Failure |
1,545.00 |
18.63 % |
| Cardiovascular Structural Heart Aortic |
874.00 |
10.54 % |
| Cardiovascular Coronary Peripheral Vascular |
618.00 |
7.45 % |
| Neuroscience |
2,458.00 |
29.64 % |
| Neuroscience Cranial Spinal Technologies |
1,250.00 |
15.07 % |
| Neuroscience Specialty Therapies |
732.00 |
8.83 % |
| Neuroscience Neuromodulation |
476.00 |
5.74 % |
| Medical Surgical |
2,072.00 |
24.99 % |
| Medical Surgical Surgical Endoscopy |
1,596.00 |
19.25 % |
| Medical Surgical Acute Care Monitoring |
476.00 |
5.74 % |
| Diabetes |
694.00 |
8.37 % |
| Other segment |
32.00 |
0.39 % |
| U S |
4,237.00 |
51.1 % |
| International |
4,055.00 |
48.9 % |
| Reportable net sales U S |
4,223.00 |
50.93 % |
| Reportable net sales International |
4,038.00 |
48.7 % |
| Cardiovascular U S |
1,405.00 |
16.94 % |
| Cardiovascular International |
1,632.00 |
19.68 % |
| Neuroscience U S |
1,689.00 |
20.37 % |
| Neuroscience International |
769.00 |
9.27 % |
| Medical Surgical U S |
893.00 |
10.77 % |
| Medical Surgical International |
1,180.00 |
14.23 % |
| Diabetes U S |
236.00 |
2.85 % |
| Diabetes International |
457.00 |
5.51 % |
| Other U S |
15.00 |
0.18 % |
| Other International |
17.00 |
0.21 % |
| Ireland |
28.00 |
0.34 % |
| Total other countries excluding Ireland |
8,264.00 |
99.66 % |
| United States |
4,237.00 |
51.1 % |
| Rest of world |
4,027.00 |
48.56 % |
| Total |
8,292.00 |
100 % |
Q3 three months ended (Jan 24 2025)
|
| Revenue Growth rates by Segment |
Y/Y Revenue
% |
Q/Q Revenue
% |
| Reportable net sales |
2.8 % |
-1.27 % |
| Cardiovascular |
3.69 % |
-2.1 % |
| Cardiovascular Cardiac Rhythm Heart Failure |
5.1 % |
-2.09 % |
| Cardiovascular Structural Heart Aortic |
3.68 % |
-0.79 % |
| Cardiovascular Coronary Peripheral Vascular |
0.32 % |
-3.89 % |
| Neuroscience |
4.37 % |
0.29 % |
| Neuroscience Cranial Spinal Technologies |
3.82 % |
1.3 % |
| Neuroscience Specialty Therapies |
0.83 % |
-0.68 % |
| Neuroscience Neuromodulation |
12 % |
-0.83 % |
| Medical Surgical |
-1.89 % |
-2.63 % |
| Medical Surgical Surgical Endoscopy |
-1.24 % |
-3.21 % |
| Medical Surgical Acute Care Monitoring |
-3.84 % |
-0.42 % |
| Diabetes |
8.44 % |
1.17 % |
| Other segment |
-39.62 % |
- |
| U S |
2.84 % |
-1.56 % |
| International |
2.19 % |
-1.07 % |
| Reportable net sales U S |
3 % |
-1.47 % |
| Reportable net sales International |
2.62 % |
-1.03 % |
| Cardiovascular U S |
2.33 % |
-2.02 % |
| Cardiovascular International |
4.88 % |
-2.16 % |
| Neuroscience U S |
8.55 % |
0.72 % |
| Neuroscience International |
-3.75 % |
-0.65 % |
| Medical Surgical U S |
-5.7 % |
-5.4 % |
| Medical Surgical International |
1.37 % |
-0.25 % |
| Diabetes U S |
5.36 % |
1.72 % |
| Diabetes International |
9.86 % |
0.44 % |
| Other U S |
-25 % |
-16.67 % |
| Other International |
-50 % |
-10.53 % |
| Ireland |
3.7 % |
-3.45 % |
| Total other countries excluding Ireland |
2.51 % |
-1.31 % |
| United States |
2.84 % |
-1.56 % |
| Rest of world |
2.16 % |
-1.06 % |
| Total |
- |
-1.32 % |
Q3 three months ended (Jan 24 2025)
|
| Income by Business Segments |
Income
(in millions $) |
%
(Profit Margin) |
| Total |
1,303.00 |
15.71 % |
Q3 three months ended (Jan 24 2025)
|
| Income Growth rates by Segment |
Y/Y Income
% |
Q/Q Income
% |
| Total |
- |
1.96 % |
|
|
